[Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)].
A novel measles-mumps-rubella vaccine (Priorix) has been marketed by SmithKline Beecham. It contains live attenuated virus with measles and mumps strains slightly different from those present in MMR VAX (Pasteur Merieux MSD). The indications and contraindications are similar for both vaccines. Immunogenicity is also equivalent as well as general reactogenicity. By contrast local symptoms were reported significantly less frequently after Priorix.
Senterre
J
J
Département de Pédiatrie, Université de Liège.
D000276:Adjuvants, Immunologic; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008458:Measles Vaccine / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology; D012411:Rubella Vaccine / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology; D014611:Vaccination; D017778:Vaccines, Combined / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology
D000276:Adjuvants, Immunologic; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D017778:Vaccines, Combined